Predict your next investment


See what CB Insights has to offer

About Escient

Provider of audio and video products that meld the power of the Internet seamlessly with intuitive home-entertainment devices. The company's products and services are designed to enhance the entertainment experience by providing ways to access music, movies, and related content throughout the home. It possesses a portfolio of designs for new products including media servers, DVD systems, remote players and networking, and streaming devices, that are brought to market through a channel of over 800 locations throughout the United States, Canada, Europe and Mexico, and in partnership with other global consumer electronics brand. [Keywords: home entertainment*, audio*, video*, media*, internet*]

Escient Headquarter Location

6640 Intech Boulevard Suite 250

Indianapolis, Indiana, 46278,

United States


Latest Escient News

Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Trial of EP547, a MRGPR-targeted Therapy to Treat Cholestatic and Uremic Pruritus

Sep 16, 2020

September 14, 2020 Proceeds support clinical development for lead program in cholestatic and uremic pruritus and second program for mast cell-related diseases Financing round led by Sanofi Ventures and Cowen Healthcare Investments and included new investors Redmile Group and Perceptive Advisors Jason Hafler, Ph.D., of Sanofi Ventures and Kevin Raidy of Cowen Healthcare Investments join Escient board of directors SAN DIEGO--(BUSINESS WIRE)--Escient Pharmaceuticals, Inc., an industry-leading company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, underserved medical needs across a broad range of therapeutic indications, today announced the completion of a $77.5 million Series B financing and the initiation of a Phase 1/1b clinical trial of EP547, a MRGPRX4-targeted product candidate to treat cholestatic and uremic pruritus. The round was led by Sanofi Ventures and Cowen Healthcare Investments (CHI) with participation by new investors Redmile Group and Perceptive Advisors. All of the company’s existing investors, including The Column Group, 5AM Ventures, and Osage University Partners, participated in the round. Escient discovered and is developing EP547 based on the novel finding of disease-related accumulation of key metabolites that specifically activate the MRGPRX4 itch receptor and will use these proceeds to support clinical development. The company is developing a portfolio of MRGPR-focused therapeutics including a second program targeting mast cell-based MRGPRX2 that is anticipated to play a role in a number of indications in various therapeutic areas. “In just over two years since our launch, we’ve made significant progress developing our platform and pipeline. We have advanced both our understanding of the role MRGPRs in a number of therapeutic areas and our methods for drugging them to potentially treat several diseases based on novel and specific mechanisms of action,” said Alain Baron, M.D., Chief Executive Officer of Escient. “Through our work, we’ve identified promising drug candidates that we are advancing into clinical development with the potential to build a pipeline of class-leading, once-daily, oral therapeutics to address debilitating diseases.”   Effective treatments for severe pruritus associated with cholestasis and uremia are sorely needed. Drug development to address pruritus in these conditions has been hampered by the lack of basic biological knowledge of their specific mechanisms. Cholestasis occurs in chronic adult and pediatric conditions wherein 30-100% of patients experience moderate-to-severe itch. Hemodialysis and end-stage renal disease are largely adult conditions with up to 55% of the population experiencing itch. “Current treatment options for cholestatic and uremic pruritus are non-specific, largely ineffective, and have significant side effects,” said Marcus F. Boehm, Ph.D., Chief Scientific Officer of Escient. “Based on our preclinical discoveries, we believe we have the opportunity to develop a mechanism-based, well-tolerated, rapidly acting and highly effective novel therapy for these patients with the potential to make a significant difference in their lives.”   The Phase 1/1b trial of EP547 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EP547 in healthy subjects and subjects with cholestatic or uremic pruritus. In conjunction with the financing, Jason Hafler, Ph.D., of Sanofi Ventures and Kevin Raidy of CHI have joined Escient’s board of directors.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.